Вы находитесь на странице: 1из 31

1/2004

-

1998 .

:
,
,



.. , .. , ..



.. , ..

,
-
,

.

:
..
..
..
..
..
..
(. )
..
( )
..
..
B.C.
..
..
..
( )
..
:
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. (-)
.. ()
.. (-)
.. ()
.. ()
.. ()
.. ()


,

.. , .. , .. , .. ,
.. , .. , .. , .. ,
..
6
-D,


.. , ..
11

-
.. , ..

16


:

.. , .. , .. ,
.. , .. , .. ,
.. , .. , .. ,
.. , .. , .. , .. ,
.. , .. , .
20


.. , .

.26



..

:
117036, , . . , . 11. .
E-mail: rozh@endocrincentr. ru
. .. ... ..
. 016589 10.09.97. 60x90/8. 5000 . 742.
. ISBN 5-7886-0002-5. , . .

. .
.

2003 . , ,

32

1/2004

.. , .. , ..
1
3 . .. ,
1997-2001 ,
.
1:3,1, .
62,7 158,8, 161,1 265,8 ( 99,1 203,6 100 000 .
). :
, - .


.
,
, ,
.
[3, 5, 6]

() .
,
, , . 2010 . 25%
,
.


50 .

( 820.0) 1 1997 31 2001


. 229,3
. , 50
18,2%.
. .
2 - . ,
.
,
. , , , .
. 100 000 5 (50-54, 55-59,60-64, 65-69, 70
).
.

5 356 (86 270 ) 162,2 100 000 1 : 99,1 203,6 100 000 -. 1:3,1.
(<0,001).

62,7 100 000 1998 158,8 2001
(<0,001), 161,1 1998 265,4
2001 100 000 (<0,001).
; 141,3 223,1 100 000
, 1,6 (<0,001), 1,64 , - 1,44 (<0,001) (. 1).

. 2.
, 55 59
2 , 2,7
50-54 . 69 . 70
, 3,3
(<0,001). 65-69 ,
5 , .
70 : 332,7 652 100 000 , (<0,05). , 60 64
, .
-'
[1, 3]. . . [3],
^ ,
, .

.
174 (45 , 129 ) , 182 (41 , 141 ) . .
, 1:2,8 1:3,4 (<0,05).
[11].

1/2004



.. , ..
(. - . . . ),
(. - . )
( - - , . .. ).
() . . .
I - , ;
,
.
, . ,
(, ). . ( ) [5]
[8].
[5, 10].

,
. ,
[2].

() .


67
39 .
, , ( 3.3),
, , - , (
3.1-3.2).
51,37+0,52 , 52,080,78 ,
- 21,54+0,45 28,751,23 .
I
49 , II - 18 .
. , , , . II
.
I 27 , II 12

. I - , II .
,
, , 1-4 (0 - , 1 - , 2 -

, , 3 -
, 4 - , ', ).
.
25 , 18 - 8 -
. 49,17+0,33 , - 50,240.49 ,
- 20,740,62 . I
15 , II - 3 . II . I 21 , II - 5 .
,
, , , (
) .

NORLAND (USA). L: - L? - L4 . - Z-. , , ,
, . Z
,
.
: 1 SD, >- 1SD, <-lSD, >- 2,5
SD ,
- 2,5 SD - .
:
- () - () , (/),
- () - .
() Achilles +(Lunar,
USA). , ( , ). Stiffhes - -

1/2004


i
Z
Z -
BMD
- - - -
- -

0,42*

0,38*

0,37*

0,37*

0,33*

0,11

0,42*

0.37*

0,36*

0,3*

0,45*

0,33*

0.33*

0,42*

SOS

0.40*

0.35*

0,31*

0,44*

0,34*

0.17

0.43*

BUA

0,37*

0.3!*

0,39*

0,34*

0,26*

0.18

0.37*

0.39*

0.33*

0,39*

0,37*

0,32*

0.13

0,43*

*-<0,05.
(). SD . - Z-.
:
(),
;
()
() - ,
, , ;
(, %),
. =0.5(+),
=(--50)/75 100; =(-1380)/180 100.
, ,
20 .
Microsoft
Excel Windows , / : .


12 (18.46%),
- 36 (53,73%).
26 (40%). 5 (7,7%), -
19 (28,35%).
8 (20.51%), - 16 (41,03%).
2 (5,13%) 14 (35,9%) .
: 4 (10,26%),
- 14 (35,9%) .

5 (20%), - 16 (64%) . 8 (32%) .
40% .
.
(I ) ( , )
39 (58,2%) 43 (64,2%)
( -
).
( , ) 25 (37,31%) 39 (58,2%) .
(II )
,

25 (64,1 %) .
35 (89.74%) . 20 (51.3%) 19 (48.7%) .
25
(III ) ,
48%.
- 52% . 44% 60% .
, , ( >0,05) .
. [1,
3]. , ,
,

[4, 7, 8]. .
.
. .


.
,
.
,
.

SUMMARY
The aim of our study was to evaluate the frequency of concurrences
values of mineral bone density in patients with vibration disease and
dust lung diseases. Values of mineral bone density were estimated with
spine x-ray absorbtiometry and ultrasound densitometrv ofcalcaneus
coincided with high frequency. We revealed a direct weak correlation
between parameters of x-ray absorbtiometry of axial skeleton and
ultrasound densitometry ofcalcaneus.

1. .. : .
. .. 2002.40 .
2. .., . : , / . . Eular Publisher.
Basel. 19%. 139 .
3. ...
.., , ..
//. . . 1996. 12. . 1-5.
4. Huddkston D.J., Rockwell D.. Kuhird D. N.. Harrison R.D. Bone mass
in lifetime tennis athletes //J. Amer. Med. Assoc. 1980. V. 224. P. 1107-1109.
5. Karlsson MX.. Obrant K.J.. Nillson B.E., Johnell O. Bone mineral
density assesed by quantitative ultrasound and dual energy x - ray
absorbtiometry // Acta Orthop. Scand. 1998. 69. P. 189-193.
6. Kaufman J.J., Einhom T.A. Perspectives: ultrasound assesment of bone/
/ J. Bone Miner. Res. 1993. 8. P. 517-525.
7. McClarke R.L. Jonson D.. Kind M.E., White M.W. X-ray bone
densitometr. In: Mazess R.B, (Ed.): Procedings forth international conference
on bone measurement. U.S. Dept. of Helm and Human Service: NIH
Publicfhion No. 80-1938. 1980. P. 329-342.
8. Nillson BE., Andersson St.M., Havdrup ... Weslling N.E. Bone
mineral content in balet dancers and weight lifters, hi: Mazess R.B. (Ed.)
Proceedings fourth international conference on bone measurement. US Dept.
of Health and Human Services. NIH Publication No. 80-1938. 1980. P. 81-86.
9. Shott A.M., Weill-Engerer S., Hans D., Duhoeuff P.J.. Delinas PR.
Meumer PJ. Ultrasound discriminates patients with hip fracture equelly well
as dual energy x-ray absorbtiometry and independently of bone mineral
density// J.Bone Miner. Res. 1995. 10. P. 243-249.
10. Yeap S.S., Pearson D., Cawte S.A.. Hosking D.J. The relationship
between bone mineral density and ultrasound in postmenopausal and
osteoporotic women// Osteoporosis Int. 1998. 8. P. 141-146.

1/2004



,

1

.. , .. ', .. , .. ,
.. , .. ', .. ', .. ', .. '
, . ,
0 Ml , . ,
..
1

, - ( ) ( ) 119 ( - 59, - 60) (), , 20 76 . 3 , KT/V - 1,41+0,15 .


() 3 : 1- (
130-260 /); 2- ( >260 /); 3-
( <130 /). 4 -
() 1 2. 3 4 . .
40-55% . (<0,05),
. () (
-0,32 -0,5, <0,01), . , - .
. (
) . , , ,
() ,
.

I

.
,
. ,
Stehman-Bren CO. et al. [20],
4,4 , 4 , . 2,4 , < 61 /, ,
62 202 / [8].
,
[7,13]. , , ,
[16].
,
(DEXA), - , [9].
,
(, ,
, ,

, , [4]), , ,
. :
1) - ;
2) 1- , 1,25 (OH),D,;
3) ;
4) , ;
5) ;
6) ;
7) ;
8) ;
9) ;
10) ;
11) (
);
12) - .
,
, 2-4 [18, 23].

1/2004

() [11]. ,
450-500 /, ,
[10, 22].

D
(VDR). . Kochama et al., , , A, t f [14].
1 - ,

. .
, , , ,
, [6,19].


, . -
.
,
. .

119 ( - 59, - 60),


20 76 . 1 225
, 2228 . , , :
( 10% ),
, , , .
Integra, Cobe,
Innova 3 4-5 , KT/V - 1,410,15.
Cobe
Hemophan 151 160 /.
1,5 /.
( ,
) 1 .
( 15-65 /) 1 .
()
(T-score).

LUNAR ( PRODIGY)
, . - (
). , : T-score -2,5
T-score -1 -2,5 .

Statistica 6,0
() (SD), t- , T-score, , } ( ).
< 0,05.


4 :
1 - (130-260 /
);
2 - ( >260 /);
3 - ( < 130
/);
4 - .
2228 .
. 1 2.
."1
, , 48-50 .
- 39^40 .
- . 2.
. 2,

.
,
.

.


. , .. . 3,30,2 / [2], - [20].

[12,23]. ,
, ,

59
Min-raax
60
4817.7
19-76
50 12,5
5
8
25-65
,

39+13
4013
19-76

Min-max
26 74
29 54
26-74

119
13
L2-L4

. 2.


1 , /

130-260

11
. /
MSD
15-65
20251

,
/
2.05 2,80 2,3+0,16

,
/
0.81-1,62 1.79+0.37

,
T-Score
0.1 1.2

3
<130
44

13

7901527 * 4322*

1671305*

2 '\ II
>260

52

1/3

V5+O.16 2,68+0.33* 2.58+0.38*

1.81+0.44

79+22*

1,6+0.5

0.7+2.9*

1,58+0.46

. 3.


3

0,53

*<0,05 1 .

...

10
1
2

%
77
8
15

, / MSD
48.536
126
314: 1248

13

(T-Score)
,
,

. 1.
-

0,21
=0.11
-0.32
=0.01

-0.22
=0.09
-0.50
=0.0005

0.24
=0.07
-0.33
=0.01



[18].
[10].
. 2, 2 ,
. 3
, . , ,
, , 43,7%
. 37% - , 9,2% - .

1/2004

10%
(39-4013 )
(. 2,3). [2]. , 1,
. J.M. Olmos et al.
, ,

1 [17]. .
. 3, 10 13 , 2 (15%) .
, , : , DEXA,
,
.
- : -0,57 1,63, -1,161,13,
-1,351,4 (. 1).
(. 2) 40-55% ( ).
.
(<0,05), . (. 3).
-
, , , .
(. 4).

[3,21].

. , , [5].
. , ,
, , ,
[1].
- ,

, .
5. (130-260 /
) . - ,
. -

5
- DEXA,

(, /)


(T-Score)
%

(T-Score;
%


(T-Score)
%

1 2 3 4
130-260
>260
<130

11
44
52
13
-0.520.46 -1.48+1.15*
18/0

-0.30.93
10/0

0.660.47
0/0

52/17*

-0.871

-1.57+-1.02*

38/4

33/33 *

-1.731.38* -0.531.03 -1.51.79*


34/26 *

16/0

38 /25*

-0.91 1.68* -0.431.76* -0.871.64 *


34/15*

32/9*

25/8

*<0,05 1 .
6
-


(T-Score)
(T-Score)
(T-Score)

.
/
=-0,3 <0,05
=-0.46 <0,05
='0, >0,05

r - .
.
. ,
,
,
.
,
.

( r=-0,06
(>0,05), r-0,12 (>0,05)).
. 5, .
.
.
-
(=-0,3) (=-0,46), <0,05,
[12]. ( )

1/2004
(. 6), A. Gerakis et al.

(=-0,58).
19,31% 26,42% , - 26% 74% .

[12].
,
, , . . , ,
, .

,
.
, .

.
4. , .
5.

.
6. , , , , ,

.

SUMMARY
There were estimated and analyzed PTH, Ca, P bone
Alkaline Phosphatase and bone mineral density (BMD) in 119
haemodialysis patients (59 male and 60 female). BMD was
measured in lumbar spine, hip and forearm. Al patients were
divided on 4 groups: group 1 - with PTH level fromBO to 260
pg/ml; group 2 - PTH> 260pg/ml; group 3 -PTH< 130pg/ml.
Patients with diabetes in haemodialysis were analyzed separately
- group 4. Hypercakemia was revealed in the most patients of
groups 3 and 4. The most patients of all groups showed
hyperphosphatemia, but there was no difference between groups.
Osteopenia and osteoporosis were discovered in different bone
sites in 40-55% of patients. The frequency of osteoporosis in
lumbar spine was more in women significantly. There was
negative correlation between BMD and age in women only. The
most patients with optimal levels of PTH showed normal BMD.
The patients of group 2 (secondary hyperparathyreoidism)
demonstrated low BMD in cortical bones (T=~ 1,48+1,15 in
femoral neck and -1,73+1,38 in forearm). While the most
patients of group 4 have got signs ofadinamic bone disease, low
BMD was revealed at all measured sites of these patients.

1.
40-55%
.
2. ,
43,7% , 37% - , 9,2% - . 10% .
3. , , 130 260 /, .. 2-4

:
i

1. .., ... .. ( ) // . 2000. 3. . 29-36.


2. ... ..
// . 2002. 1. . 24-27.
3.
. , 13-14 2002 .
4. .. : . .: . . 2000. . 33-37, 52-54.
5. / .. . .: , 2003. . 221.
6. . .. . . 1
( ) // . 1999. 1. . 2-5.
7. Abramowitz M. Bone Densitometry. Medical Letter// Drugs and
Therapeutics. 1996. V. 38 (988). P. 103-104.
8. Atsumi K, Kushida K, Yamazaky et al. Risk factors for vertebral
fractures in renal osteodystrophy//Am J Kidney Dis. 1998. V. 31. P. 607-617.
9. Christiansen C. Osteoporosis: diagnosis and management today and
tomorrow// Bone. 1995 Nov. 17 (5 Suppl.). P. 513S-516S.
10. Coen G., Mazzaferro S. Bone metabolism and assessment in renal
failure// Nephrone. 1994. V. 67. P. 383-401.
11. Dyaz Corte . Na ves M.L., Gomez C.. Vazquez A.. Barreto S., Carmata
J.B. Prevention, results from a multicentre enquire// Nephrol. Dial. Transplant.
1998. V. 13 [Suppl 3]. P. 51 56.
12. Gerakis A., Djidakis D.H., Kokkinukis E. et al. Correlation of bone
mineral density with the histologicol findings of renal osteodystrophy in
patients on haemodialysis // Nephrol. 2000. V. 13. P. 437-443.
13. Keltic S. E. Measurement of Bone Densitometry with Dual-Energy X-Ray
Absorptiometry (DEXA)//Cole HM Med. JAMA. 1992. V. 267. P. 286-294.
14. Kohamu K. Uemasu /, Kawasaki H.. Nanba E. ami Tokumolo A.
Association between Vitamin D Receptor Gene Polymorphisms and Renal
Osteodystrophy in Patients on Maintenance Hemodialysis Yonago Acta
medica // Nephrol. Dial. Transplant. 2000. V. 43. P. 27-38.
15. Llach F. Renal osteodystrophy. In: Replacement of renal function by
dialysis/Fourth edition. Ed by Winchester J.F.//Kluwer academic publishers.
1996. P. 1159-1235.
16. Maarten W. Taal, Tahir Masud. Desmond Green and Michael J. D.
Cassidv. Risk factors for reduced bone density in haemodialysis patients //
Nephrol. Dial. Transplant. 1999. V. 14. P. 1922-1928.
17. Olmos J.M., Perez-Castrillon J.L.. Garcia M.T. Bone densitometry
and biochemical bone remodeling markers in type I diabetes mellitus //Bone
and Mineral. 1994. V. 26. P. 1-8.
18. Quarks L. Lobaugh .. Murphy G. Intact parathyroid hormone
overestimates the presence and severity of parathyroid-mediated osseous
abnormalities in uremia II}. Clin. Endocrinol. Metab. 1992. V. 75. P. 145-150.
19. Seino Y. and Ishida H. Diabetic Osteopenia: Pathophysiology and
Clinical Aspects // Diabetes Metabolism Reviews. 1995. V. 11. P. 21-35.
20. Stehman-Bren CO.. Shenard D.J.. A.L. el al. Risk factors for
hip fracture among patients with end-stage renal disease// Kidney Int. 2000.
V. 58. P. 2000-2005.
21. Toroptsova N.. Kovalev V., Ushakova M., Benevolenskaya L.
Osteoporosis and osteopenia prevalence in women population of Moscow
region // Osteoporosis Int. 1998. V. 8. P. 19.
22. Torres A.. Lorenzo V., Hernandez D. et al. Bonedeseaseinpredialysisis,
hemodialysis. and CAPD patients: evidence of a better bone response to PTH
// Kidney Int. 1995. V. 47. P. 1434-12.
23. Wang M.. HerczG., SherrardD., SegreG., Pei Y. Relationship between
intact PTH (1-84) parathyroid hormone and bone histomorphometry
parameters in dialysis patients without aluminum foxicity // Am. J. Kidney
Dis. 1995. V. 26. P. 836-844.

1/2004


-D3

.. , ..

-D3
. , D
,
. . . .
^ ,
, , [4].
, [9]. , - ,

[12]. [1, 15].
,

, [2, 11, 14].
, [5, 7],
()
D [13].

[6,10].
D , , ,
, . -


, .


-D,
.


- 180-220 .
4 ( 20 ): 1 - ,
-D3 (
D3 - ), 2- - ;
3- - , D3 4- - . : -D3 8,33 /. 1 ,33 /. ,
8,33 /. 1 ( 4,167 /
. 0,667 /. 100 ). 40 .
. ( , ) 10% ,

1/2004

.
, .
MOB -1 -15 - 289 . ,
.
NIKON MICKOFLEX AFX - DX, 11.

[3] :
( %),
( ), ( ), ( ), ( ),
( %), ()
2
( ), (
2
%), () ( ).


(), (), (t).

-D,
, ,
-D, , (6,1 1,2%, <0,01),
(4,91,1%, <0,05) ,
(10,61,2% 9,52,0% ). (
2
- 0,8+0,1 , <0,01, 2
- 2,00,2 , <0,05),
, 2
2
(2,00,6 3,1 0,5
) (. 1). .
- , :
(7,5+0,9%, <0,05),
(6,31,8%, >0,05). , , (
2
-1,40,5 , >0,05, - 2,5+0,7

, >0,05),
.
,
.
, -Dj
, . ,
( 4,40,8 , <0,05, - 9,50,9%,
<0,05) (2,7+0,3
6,6 1,1 ). (>0,05),

.
.
.
-D, ( - 2,90,5 , - 6,3 1,4 ),

(>0,05).
(>0,05).
, , ,
.
, ,
,
[8].
-D,
.
( 58,71,9 , <0,05, - 52,61,7
, <0,05) ( - 41,24,7 , <0,05,
- 32,43,8 , <0,05) .
. ,
68,92,7% (<0,05), 56,52,4% (<0,05), -

1/2004

(59,73,8% 49,82,2%). ,
, , - ( -72,3+4,1%, >0,05, 58,7+3,6%, >0,05) , -D,. .

. ,
(>0,05)
(4 )
.
,
-D,
.
, ,
( - 55,7+2,6 , >0,05, - 50,42,2 , >0,05)
( 49,6+5,4 , >0,05, - 38,2+5,6
, >0,05) (. 1), , .
(64,3+3,1%)
(53,1 +2,8%) (>0,05),

. 3 (15%) 20 ,
12 (60%) - , 5 (25%) - ( ),
, 22 (55%)
, 18
(45%) - . -D,
, , , . , 138,53,2 ,
- 146,2+2,2 , - 135,42,3 144,1+3,1
, >0,05.
, ,

, .
, . , -D ,
(<0,05).



(>0,05). ,

,
, , 62,5% (<0,05). ,
-D, ,
.
.
, , -D,,
(
- 9,50,7%, <0,01, - 8,41,2%, <0,05) ( :
- 1,1 0,2 , <0,05, 2
2,30,7 , <0,05)
(. 2). (10,81,2%, <0,05),

(10,22,3%, >0,05)
(16,32,5% 15,1 3,2%) ).
( :
- 2,40,6 , 2
3,81,4 , >0,05),
2
:
(3,7+1,3 5,21,2 )
.
, *
-D,, ( - 4,20,5
, <0,05, - 9,41,1 ,
<0,05) (2,1 0,7
5,91,4 ). , , [8].
, -D,, -

1/2004

: * - , * - <0,05, ** - <0,01, / - ;
- , -
.
2



-D3

,
=40
,% 52,64.5
44,32,8

-D,
=20
=20
62,52.1*
55.73.4/
51,62,4*
47,52,6/

128,22.8 135.52,2*
137,82,6 145,42,4*

, 78,412.4 53,88.4^
60,610,2 46,27,3"/

131.22,5/
140,62,1/
53,48,7/

44.93.8
46.21,9

54.22.5*
50,9+1,4*

49.62.1/
48,62,3/

2,10,7
5,91,4
15,42.6
14,22,3

4,20,5*
9,4+1,1*
11,92.1/
10,81,8/

2.30,9/
5,51,6/
13,62,4/
12,52,2/

,0/)

16.32.5
15,13,2

9.50,7**
8,41,2*

10.81.2*
10,22,3/

3,71,3
5,21,2

1.10,2*
2,30,7*

20,6/
3,81,4/

: * - , * - <0,05, ** - <0,01, / - ; , - .

,
( 3,5 11 )
. ,
( - 11,92,1 2, 10,81,8 2, >0,05), , ,
, ,

.
.
, ( - 2,30,9 ,
- 5,51,6 ),
(>0,05).

, -D3
.

.
, , , [3]. D3,
.


-D3 . , , .
, -D3
54,22,5 (<0,05),
- 50,9+1,4 (<0,05), (44,93,8
46,2 1,9 ). .
(
- 53,88,4 , 46,27,3 ), (
- 78,412,4 , - 60,6 10,2 ), (>0,05).

1/2004
-D, ,
, (. 2).
(62,5+2,1%, <0,05) (51,6+2,4%, <0,05) (52,64,5%
44,32,8%).
.

(135,52,2 ) (145,42,4 ) , ,

(128,22,8 137,82,6 ,
<0,05),

( 138,5+3,2 , <0,05,
-146,22,2,<0,05).
, , ( - 49,6+2,1 , - 48,6+2,3
) (>0,05).
( 66,1 9,3 , - 53,48,7 )
(>0,05).
( )
. 3 (15%) , , .
,
.

,
D , .
.

.

SUMMARY
The influence ofcalcium-D ? N corned and calcium
carbonate matters on histomorphometric parameters of
bone tissue during pregnancy and lactation of testing
animals was analyzed in comparative aspect. The
quantitative and qualitative changes showed that combine
usage of calcium carbonate and vitamin Dt during
pregnancy and lactation had positive effect on bone mass
expressed in bone mass stabilization and trabecular bone
microarchitecture safety. The effectiveness of combined
therapy was determined by it's ability to keep an optimal
bone formation speed and to suppress bone resorbition
simultaneously. Treatment with only calcium supplement
did not fully prevent the bone loss.

1. ... ... . .
//
. 2001. 1. . 8-11.
2. . // XIV . (, ). 1999. . 43.
3. .., 111 .. . , , . .: . 2000. 558 .
4. . . .. // . 1998. 1. . 33-35.
5. .., . // . . .-. 1996.
4. . 32-37.
d.ChanG.M., McMurry M., Westover . et al. Effects of increased
dietary calcium intake upon the calcium and bone mineral status of
lactating adolescent and adult women // Am. J. Clin. Nutr. 1987. V.
46. P. 319-323.
7. ChesneyR. W., SpeckerB.L.. MimouniK, McKayC.P. Mineral
metabolism during pregnancy and lactation // In: F.L., Favus
M.J.. eds. Disorders of bone and mineral metabolism. New York:
Raven Press, 1992. P. 383-393.
8. Compston J.E., CroucherP.I. Histomorphometric assessment
of trabecular bone remodelling in osteoporosis // Bone Miner. 1991.
V. 14. P. 91-102.
9. Hordon L.D.. Raisi M., Aaron J'.E. et al. Trabecular architecture
in women and men of similar bone mass with and without vertebral
fractures: Two-dimensional histology // Bone. 2000. V. 27, 2. P.
271-276.
10. Kent G.N.. Price R.I., Gutterbridge D.N. Acute effects of an
oral calcium load in pregnancy and lactation: findings on renal
calcium conservation and biochemical indices of bone turnover //
Miner. Electrolyte Metab. 1991. V. 17. P. 1-7.
11. Kent G.N., Price R.I.. Gutterbridge D.N. el al. Effect of
pregnancy and lactation on maternal bone mass and calcium
metabolism. Osteoporosis Int. 1993. V. 3. S.I. P. 44-47.
12. Legrand E., Chappard D., Pascaretti C. et al. Trabecular bone
microarchitecture and male osteoporosis // Morphologic. 1999. V.
83, 2 6 1 . P. 35-40.
13. Marie P.J.. CancelaL., LeBoulch N.. MiravetL. Bone changes
due to pregnancy and lactation: influence of vitamin D status // Am.
J. Physiol. 1986. V. 251. P. 400^06.
14. Sowers M.F., Corton G., Shapiro B.L. Changes in bone density
with lactation // JAMA. 1993. V. 269. P. 3130-3135.
15. Purfitt A.M. The physiologic and pathogenetic significance
of bone histomorphometric data. In: F.L.. Favus M.G. eds.
Disorders of bone and mineral metabolism. New York: Raven Press.
1992. P. 475^189.

1/2004

-
.. , ..
-
( - . . ),
() /5 51 69 ' .
10 1000 12 .
(12 ) 1000 . 12
8,2%, - 3%,
, ( 1,4% , 0,4% ).
:
16,9%, (<0,05), 42%> (<0,01) 15,1% (<0,001) 12 .
- , . 15
9 12 . . 4 6 12
( ).
, 4 . 20%) .
.

, ,

,
. - ( ) ( - MERCK SHARP & DOHME, USA), .
(4--1-). in vitro, 1000 , , , , .
(2-3^-7-),
() , [4,9,7].

- : , , , ,
,
.

.


, - ,
.

,
27 51 69
, 4 19 .
15 , 1 (10 )
30 200 12 .

, -
D,, 1200 (500 ) 200 . D
2 (1000 ). 9
12
: 10 2 ,
5 - 3 1 - 4
. 12 ,
- D, 2
(1000 ).
: 3
: - 2
-2,5 SD (<0,86 / );
.

1/2004

,
2

L1-L4, /

, /'
:


(=15)
62,5 6,33

(=12)

60 5,2

12,4 5,04
0,73 0,07
0,65 0,12

15.5 4,4
0,75 0,07
0,67 0,09

13,5%
20%

16%,
16%

2

-
-

,
/
- 156,07

49,2
134,62

6 .
26,0
130,54

12 . 37,6
0-6< 0,11
0-12< 0,05

,
/

- - - -
,
,
/
/ , .
,
/

1,33
0,3
1,21
0,05
1,21
0,08

1,12
0,25
1,03
0,17
1,04
0,31

0,28
0.08

0,09
0,03

9,17 22.49
8,9
5,3

130,5
36,9

5,32 20.65
4,5
8.3

110,08
26,6

0.01

0.001

0.09

+5,4%*

1,8"/

. 1.
(%) 6

. 2.
(%) 12

. 3.
,
1

. 4.
,
1

1/2004

: , , , , ,
5 , , , , (, , SERM, , , ) 6
.
,
, 6,12,
24 .

() (- 4 ) Hologic QDR 1000 W.
- .
, -
1 ( ).

. , 6 12 .
Statistica,
Microsoft Windows 95.

. :
/


. 1 -
, .
, .
( ), 2 i , 2 ,
1
- .
, L,2
L4 0,730,07 / ,
2
0,650,12 / , 0,750,07 /
2
2
0,67+0,09 / . . 1 2 6 12
. 6
5,4% (<0,01), 12 - 8,2%, ( -

<0,001). U.A. Liberman et al. [7]


[9, 1,2].

12 - 3%
(<0,05).

[9,7,1,2].
,
- D,, 12 .
1,4% 0,9% - ,
. ,
.
1
. 3, 4.
. 3 6 1 - 12 ( ).
,
4 .
,
[8,9,11].
.
. 2
( , ) - (

) . , , . 3 , 3 - 2 - . .
1 , - 6, - 3 .
12 16,9%
(<0,05), - 42% (<0,01)
- 15,1% (<0,001). -
,
. ,
- . -

1/2004

[1, 5]. .
Garnero ,
,
3-6 [6].
. 1 - . 12-
, .
5 , -
1 .
14 .
, .
,
. ,
- 20% . .

10 ,

. . - 70 1 .
- , : 70
1 , 35 2 10 .
12
.

70 1 . , 70 1
10 ,
[12].

1. 10 (5,3% - 8%)
(2,12% - 4,2%).
2. (5001000 ) , .
3. .
4. ,
, ,
12- .

10
3^4 .
SUMMARY
We studied the effect of alendronat treatment on bone
mineral density and tolerability ofalendronat in 15 women (aged
51-69years) withpostmenopausalosteoporosis (group 1). The
daily dose of alendronat was 10 mg with superinduced calcium
1000 mg per day during 12 months. In aged match conrol (12
women) group (group 2) only calcium 1000 mg was taken. In
group 1 after 12 years of treatment it was established a
significant increasing of values of bone mineral density in spine
(8,2%) and hip (3%), while in group 2 bone mineral density
changed lightly (in lumbar spine 1,4%, in hip 0,4%)/ We found
a significant decrease serum total alkalinephosphatase -16,9%>,
serum osteocalcin - 42'%, and serum procollagen type 1
carboxyl-propeptid-15,1%) (p<0,001). 19 patients from group
1 continued treatment after 12 months. In most patients bone
mineral density increased smoothly during treatment. In the hip
we did not find significant changes of bone mineral density.
Moreover, in 4 cases bone mineral density was lower than
baseline. In 20%> cases we discoveredgastrointestitial side effects
after ainedronat treatment.

1. ... .., .. // . 1998, 2. . 33-36.


2. .., ... .. .

// . 1998. 2. . 28-32.
3. ., ... .. .
//
. .. . 1998. 3. . 29-32.
4. Black D.M., Thompson D.E., Bauer D.C., Ensrucl. et al. Fracture risk
reduction with Alendronate in Women with Osteoporosis: The Fracture
Intervention Trial. J.Clin. Endocrinol. Metab. 2000, V. 85. P. 4118-4124.
5. Chestnut C.H., McEIungM.R.. EnsrudK.E. etal. Alendronate treatment
of the postmenopausal osteoporotic women: effect of multiple dosages on
bone mass and bone remodeling. Am. J. Med. 1995; 99: 144-152.
6. Garnero P., Shin W.L., Gineyts E. Comparison of new biochemical
markers of bone turnover in late postmenopausal osteoporotic women in
response to alendronate treatment. L. Clin. Endocrinol Metab., 1994:79; 16931700.
7. Liberman V. A., Weiss S.R., Broil J. etal. for the Alendronate phase III
Osteoporosis treatment Study group. Effect of oral Alendronate on bone
mineral density and the incidence of fractures in postmenopausal osteoporosis.
N Engl J Med 1995; 333(22); 1437-1443.
8. Luckman St. P., Coxon Fr. P., Ebertim Fr. H. el al. Heterocyclecontaining bisphosphonates cause apoptosis and inhibit bone resorption by
preventing protein prenilation. evidence from structure-activity relationships
in J744 macrophages. J Bone Miner. Res., 1998; 13; 1668-1678.
9. Pols H.A..Felsenberg D.,Hartley D.A. et al. Multinational, placebocontrolled, randomized trial of the etfects of Alendronate on bone density
and fracture risk in postmenopausal women with low Bone mass: Results of
the FOSIT study. Osteoporosis Int.l999.V. 9. 5. P. 461-468.
10. Papapoulos S.E., Landman J.O.. Bijvoet O.L.M. et al. The use of
bisphosphonates in the treatment of osteoporosis. Bone. 1992: V.13: S41^19.
11. Russel R.J.J., Croucher P.J., Rogers M.J. Bisphosphonates;
Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int.. 1999;
9 (Suppl.2). S66-80.
12. Schnitzer P.J., Bond H.G., Crepaldi G. et al. For the Alendronate
Once-Weekly Study Group. Therapeutic equivalence of Alendronate 70 mg
once weekly and Alendronate lOmg daily in the treatment of osteoporosis.
Aging. Clin. Exp. Res. 2000; 12(1); 1-12.

1/2004

.. , .. , .. , ..

.. , .. , .. , .. , ..

.. , ..

.. , ..

.. , .. , .
,
(), , - 334
. DEXA
. : 1 - 124 , 12 2 , I 600 (1500 ), 200 ME , 40 (7,5 ), (1 ), (1,8) (250); 2 -117 ,
1500 ; 3 - 93 - ( ).
60-65% .
, . (+1,15%) (0,6-0,93%*), , , .
, , ( -/, 9 -2,91%),
.
, ,
. 2 , 3 -
. 1 14,4% 2 (16,2%).
2 1 1 2 .

D 75 , [6, 8, 16].
. , : , D D.

15 (1806 ) (2,5%
, 1,66% , 1,6%
1,91% ) [21]. ( - =0,79). , (=0,85) [21}. , D [13],
D
, D
,
.

10-20 . , Ettinger . [11] , 1000 (650-850 ) , .


Dawson-Hughes . [7],
( 650
) 500
, .
,
50-70% , ,
D [12,15].
, D
,
D,
, . [9] ,
D
2570%.
-

1/2004

D .
, , , -,
, , [1].

( ,
) [1,22],
. ,
(400 ), D
(400 ME), (3 )
(4,4%),
(2,2%) [20]. Rude [19] 5
( 19-61 , 2
200-600 )
.

1,6% 11%,
. ,
.
,

. ,
,
[14].
, [6]. ,
.
, D ()
[2].
,
, D ,

D.

/

-
.

...

26
25

60,85,8
60,85,9

25
25

62,76,0
61,4+4,3

26

58,55,1

27

57,44,1

21

57,66,6

20

55,96,1

26
124

61,96,1
59,9,3,6

20
117

64,94,4
60.54,2

, , 1 600 (1500 ), 200


ME , 40
(7,5 ), (1 ), (1,8 ) (250
), .

( 5 ) , 334 50 70 ( 59,93,6 ) .
: 1) 50
70 , 2 ; 2) -
( -1,4 -2,5); 3)
.
:
; , - ;
; ; - (), '; ( , );
10 ; , , .

: 1 - ,
(1 2 , : 1200 , 400 ME ,
80 , 15 , 2 , 3,6
500 ); 2 - , 2500 (1000 )
); 3 -
.
334 . . 1 .
-12 3 :
(), , ()
.

1


(),

, 3
, -
,


, , 25
60.1 6,9
25
59,45,5
, . 25
59,24,7
, 1 ,
18
59,35,5
,
.
0
4- : 0 - ,
1 - , 2 93
59,5+4,2

1/2004

, , 3 -
, 4 - ,
.
Lunar Hologic
12 . .
.
3 . .
(
) ()
, 6 12 .
Statistica 5,5 Windows
Biostat. Kruscall-Wallis, -, .
Wilcoxon.


. 2 . 1
.
. 2 . 1, , 65% . ,
, (, , ).

.
, ( )
, .
. 3
.
. 3, ,
- 2 3 .
,
15 ( 2

(MSD)

=93

0.71,0
1.41,1
1,21.1

=117
0,61,0
1,11,1
1,21,1

0,91,3
1,21,3
1,31,2

>0.05
>0,05
>0,05

430177

460165

370189

!
=124


()

3
(MSD)


2
(/ ) -

L2-L4

Neck

n=125

n=lll

n=96

0,9600,100

0,9710,101

0,9750,116

0,8020,091

0,8190,110

0.8450,110
0,9260,131

Total Hip

0,8920,091

0,9000,091

L2-L4

-1,760,59

-1,630,64

-1,560,69

TNeck

-1,240,67

-1,120,86

-0,890,77

T Total Hip

-0,770,78

-0,730,75

-0,390,75

8,54,0 14,87,1 )
( ) .
Total Hip, .
.
, (. 2) ,
(<0,01 - <0,001).

(<0,05) .
,
(=0,048).
. . 4 . 3
5
.
,
,
. , ,

, , Total Hip.
.

1
, 2,
3 . 3 (. 3-5). , , , 2 ,
3 .
Aloia . [4],
, 1700 400 D
, , ,
. .

1/2004
(. 5),
D ( 2
2
,

MSD, /
MSD, /
P l-3 , %
)
!
n=124 , 4 n=123
L1-L4 =125
0.9600,100
0,9680,135
<().()() 1
1,155,60
pl-2<0.001
Neck, n=124
0,8020,091
0,8130,099
<0,005
0,935,58
pl-2<0.001
, Total Hip. n= 123
0,8920,091
0,9000,096
0,594,13
pl-2<0,005
<0,01
[7.11,
T L1-L4. n=125
-1.760,59
-1.640,62
<0,001
18], T Neck, n= 124
-1,240,67
-1,190,73
<0,05
[3, 4, 10].
T Total Hip, n= 123
-0,770,78
-0,720.84

,

n=l 11
4. n=108

L1-L4, n = l l l
0,9720,107
-0,244,77
p2-3<0,001
0,9710,101

Neck, n = l l l
0,8190,110
0,8180,108
-0,425,40
p2-3<0.001

Total Hip, n=l 11


0,9000,091
0.8930,087
=0,067
-1,096,01
p2-3<0,005
T L1-L4, n = l l l
-1,630,64
-1,630.71

, ..
TNeck, n=l 11
-1,120,86
-1,180,73

, T Total Hip. n=l 11


-0,810,74
-0,730,75
<0,05
D,
=93
4, n=93
,
L1-L4, n=96
0,9750,116
0,9430,105
<0,001
-2.913,79
pl-3<0,001
Neck, n=96
0.8450,110
0,8270.104
<0,00l
-2,055,10
pl-3<0,001
Total Hip. n=96
0,9260,131
0,921 0.099
<0,001
-1,906.15
pl-3<0,001
,
T L1-L4, n=96
-1,560,69
-1.770.62
<0,001

T Neck, n=96
-0,890.77
-1.020.70
<0,001
, T Total Hip, n=96
-0.530,82
<0,001
-0,390,75

,

. , . , 2 : 65 (270
,
) 65 (64 ). . 5
.
.
(1000-1200 ) D (400-800 ME)
[3, 4, 10, 13, 21 ], 1 2
, , , , ,
.
D : 1) ,
, , ,
, ,
,
[1, 19, 20]. - ; 2) ,
, ,
,
, .
- ; 3) , ,
, - 65 .
. 6.

. 6, , ,

, , - ,

.
[5, 8, 15]. ,
* , ,
5
.
MIIKT(D % - SD)



65

65
. ,
=270
=64

,
=99 1,64,2

=26 -0,124,8
,
=90-0,154,3
=20 0,23,2
L1-L4
.
=81 -1,93,1

=16 -3,153,3
, =99 0,53,8

=26 1,917,4

=90 -1,04,8
=20 0,253,7
Neck

=81 -2,65.1

=16-1,42,8
.
4
( SD) 12

1/2004
6
-


Wilcoxon

. 1.
()

1
. 2.

()

. (), ,
.
, . . 7 , .
. 7,
, 14-16%.
, . D, .

1.


, , .
2. , ,
.
3. .
4.
14%,
. 2% .

. =99
. =26

. .

MSD(1)
, =
1,080.09
2,060,42
1,150,29
77.620,4
16376
42,2+16,1, =52
0,430.51, =99*

MSD (2)

1,130,21
2,3910,30
1,190,28
86,974,9
16461
32,46,9, =46*
0,410,18, =99*

1-2
11=124
<0.01
<0.01

<0,01

<0.0001


. =96
. =14

. .

= 110
1.11 0.21
2,020,32
1,200,29
79,214,7
14861
38,212,4, =51*
0,380,14, =97*


1,070,16
2.200,31
1,2210,31
83,8+14,3
147158
36.0+/,, =4*
0,4510,24, =97*

=110
=0.063

<0.01

. =70

. .

=70
1,070,09
1.180,28
79,413,5
15562
51,3+16,2. =25
0.380,48

1
1,0410,08
1,1610.25
79,8+14.2
152159
52,5+15,4, =25
0,3810,32

=70
<0,05

* - ;
1 - , 2 - 12 ;
- .
7
,

()

...

=124
.
14
3
1

%
11,3
2,4
0,8

18

14,4

1,6


=117
.
%
12
10,3
3
2,6
1
0.85
0,85
1
1
0.85
1
0.85
19
16.2
1

0.85

SUMMARY
A multi-central comparative opVn research to reveal of
VITRUM OSTEOMAG influences on mineral bone density,
pain syndrome in bones, index of calcium/phosphorus metabolism
was conducted. To this study we picked out 334postmenopausal
women with osteopenia. BMD was measured in lumbar spine
and proximal part of the hip with using DEXA. All patients
were divided in 3 groups: group 1-124 women treated with 2
tablets of VITR UM OSTEOMA G daily during 12 months. One
tablet contained: Calcium 600mg (1500 mg calcium carbonate),
200 ME cholecalciferol, magnesium 40 mg and microelements:
zinc (7.5 mg), copper (1 mg), manganese (1,8 mg) and boron
(250 mkg). Group 2 consisted from 117 women treated with
1500 mg calcium carbonate. 96 women were in control group
(group 3). Calcium intake rate was 60-65% lower than
normative data of it's intake with meal. During VITRUM

. 3.
(L1-L3)

OSTEOMAG treatment a significant reduction of pain in the


back and joints had been marked. In the course of the year we
observed a positive influence of VITRUM OSTEOMAG on
mineral bone density (+1,5%) and proximal parts of the hip
(+0,6+0,93%) that exceeded calcium carbonate effect, which
preserved the initial BMD in low-back spine, but didn't prevent
bone loss in the hip. BMD dynamics in patients been treated
with VITRUM OSTEOMAG differed essentially from one in
the control group (from -1,9 to -2,91%). This fact demonstrates
a reliable preventive antiosteoporotic effect of this medication.
VITRUM OSTEOMAG reduces levels ofPTH in blood that
leads to increase the level of general and ionized calcium in blood,
but does not cause hypercalcaemia. In group 2 biochemical
parameters did not change and in group 3 we observed a decrease
of ionized calcium concentration in blood. Frequency of side
effects in group I was 14,4% and did not differ significantly
from group 2 (16,2%o). Only 2 patients from group 1 and 1
patient from group 2 refused treatment.

. 4.
(Neck)

40
30
20
10

. 5.
(Total Hip)

. D
, : 100 - (1/
4) 100, 1 - , 4 , .

1. .., ... . ( ) // . 2003.


1.. 18-22.
2. . // . 2002. . 3. 1. . 2-7.
3. ... .., .., ... .., ... .. D // . 2001. 1. . 29-33.
4. Aloia J.F., Vaswani A.. Yeh J.K., Ross P.L. et al. Calcium
supplementation with and without hormone replacement therapy to prevent
postmenopausal bone loss. Ann. Intern. Med. 1994. V. 120. P. 97-103.
5. Chapuy M.C.. Ariot M.E.. Delmas P.D el al. Effect of calcium and
cholecalciferol treatment for three years on hip fracture in eldery women. Brit.
Med.J. 1994. V. 308. P. 1081. 1082.
6. Conlan D., Korula R. Serum copper levels in elderly patients with
femoral-neek fractures. Age Aaeing 1990:19:212-214.
7. Damon-Hughes ., Dallal C.E., Krall E.A. et al. A controlled trial of
the effect of calcium supplementation on bone density in postmenopausal
women. N. Engl. J. Med. 1990. V. 323. P. 878-883.
8. Dawson-Hughes .. Harris S.S., Krall E.A.. Dallal C.E. Effect of calcium
and vitamin D supplementation on bone density in men and women 65 years of
age and older. N. Engl. J. Med. 1997. V. 337. P. 670-676.
9. Dawson-Hughes B. Vitamin D and calcium: recommended intake for
bone health. Osteoporosis Int. 1998. V. 8 (suppl.). P. S30-S34.
10. Elders P.J.M.. Netelenbos J.C.. Lips P. el al. Calcium supplementation
reduces vertebral bone loss in perimenopausal women a controlled trial in 248
women between 46 and 55 years of age. J. Clin. Endocrinol. Metab. 1991. V. 73. P.
533-540.
11. Ettinger ., Genant H.K., Cann C.E. Postmenopausal bone loss is
prevented by treatment with low-dosage estrogen with calcium. Ann. Intern.
Med. 1987. V. 106. P. 40-45.
12. Gallagher J. Vitamin D treatment in osteoporosis and osteomalacia
In Osteoporosis, eds. J. Stevenson and R.Lindsav. Chapman & Hall Medical.
London, 1998. P. 243-262.
13. Gillespie W.J.. Avene/I A.. Henry D. A. el al. Vitamin D and vitamin D
analogues for preventing fractures associated with involutional and postmenopausal
osteoporosis (Cochrane Review). The Cochrane Library, Issue 1.2004.
14. Herzberd M.. FoldesJ. Zinc excretion in osteoporotic women. J Bone
Miner Res 1990:5:251-257.
15. KanisJ.A. Requirements for calcium and its use in the management
of osteoporosis. In Osteoporosis, eds. J. Stevenson and R.Lindsay. Chapman
& Hall Medical, London, 1998. P. 215-242.
16. Ooms M.E., RoosJ.S., Besemer P.D. etal. Prevention of bone loss by
vitamin D supplementation in eldery women: a randomized double blind trial.
J. Clin. Endocrinol. Metab. 1995. V. 80. P. 1052-1058.
17. Optimal Calcium Intake. NIH Consens Statement Online. - 1994. June 6-8; 12 (4): P. 1-31.
18. Rises B.L., Melton III LJ. Involutional osteoporosis. N. Engl. J. Med.
1986. V. 314. P. 1676-1686.
19. Rude R.R. Magnesium deficiency: a possible risk factor for
osteoporosis. In: Nutritional aspects of Osteoporosis. Eds. P. Burckhard.
B.Dowson-Hughes. R. P.Heaney// Academic Press San Diego. San Francisco,
New York, Boston, London. 2001. P. 263-271.
20. Shaafsma A., Pakan I. Short-term effect of a chicken egg shell powdre
enriched dairy-based products on bone mineral density in persons with osteoporosis
and osteopenia // Bratisl.Lec.Listy. 1999. V. 100. 12. P. 651-656.
21. Shea .. Wells G., Cranney A. etal. Calcium supplementation on bone
loss in postmenopausal women (Cochrane Review). The Cochrane Library.
Issue 1,2004.
22. Tobci Y., Kajita Y., Masuyama K. el al. Dietary magnesium
supplementation affects bone metabolism and dvnamic strength of bone in
ovariectomized rats // J. Nutr. 2000. V.I30. 2. P. 216-220.

1/2004




.. , .

( - .. )

. .
1 , ,
20% [27].
,
, . ,
11%, 23% ,
3,2 ,
2,2 .
: 2,4
, ,
84%) 72% .
25%
, . ,
, . ,
, 65 [30] (. 1, 2).
.

60 . . () ( 30 80
) 1,2-2% .
0,2 1,0% , 1,2
2% . ,

,
.

.
. - () ,
. Jackson et al. [17] 71%
, 32%
. . Ongphiphadhanakul et al. [32]
.
, ?

.
. , ,
MMAS 1
),
0,4% , - 1,2% [11].
. 3.
, ,
,
,
, 30 [15, 44].
(,
) -
, . ,
50 7% 30- , 70- - 22%.
, ( 98%)
: 58-60% - ,
40% - , -- ,
1-2% , . ,
,
,
, -

1/2004

. 1.


The European Vertebral Osteoporosis Study. J.
Bone Miner Res 1996; 11:1010-8.

. 4.

,
(Vermeulen A. et al, 1996)

4000

,
/

. 2.

2 ,
/

The European Vertebral Osteoporosis Study. J.


Bone Miner Res 1996: 11:1010-8.

,
/

20

40

60

80

100

. 5.
(), 2() ()
. Rochester,
Minnesota

, , .

, . . 4 [52].
,
[18, 23]. - .
-

, .
() , .

,
[42] (. 1 [20]),
[20,42,13]. . 5
. 1 , ( ,) 350
350 , ,
, [13].

1/2004

. 1, ,
2- .


2 [20], : -
() , - .
, (),
[46]. , ,
. , , [51],
, -1
- 3 [40], [53]. , -
.
, :
.
,
.
,

(. 6).
, , -1 - 3,

.
:
, - . , ,
-1
,
.


, .
.
[25]. ,
, .
80- [8, 21], 1991-1992
- [33,34],

. ,
,

. 6.
,

40

II)

IJ-10
-20

. 7.


1

(% )

(% )

-47

-83

-64

-28

+ 124

-1

[16]. , , [7, 24, 39].


[25, 12] ,
.
. . -, (), . -, -

1/2004

, [16], - [25].

, .
[36, 37,9].

, () [2]. , () . , [25],
[6]. [19].
,
[10],
. -
,
[14, 43, 28, 4, 3].

. , . , [54],
[48].
25% , ,
, ( ) -1 ( -1)
.


.
Smith et al. [43] 28
, -. , , . Carani
et al. [4], Bilerikian et al. [3] , ,

.
,
, , .
: .
, ,
-

: ,
. , .


- [50],
, ,
.

. , , - [41],
[35],
-. ,
[26].
[20, 42, 13, 46, 5, 31, 49, 1, 45]

.
, , Falahati-Nini et al. [10]
. 59 ( 68 ) ,
,
. 3-
. 4 :
, , . 3
.
, ,

,
, ,
. . 7
.
() N 1 (N-TK-1). ,
. N- 1
(-1) .
. 7, .
, , 70%
,
- 30%. -

1/2004

, . .
,
, [54, 48].
, ,
.
, - - (3, - ,
, [55]. - [38].

. , .
D [22], , .
, . .
105 42 78 ( 543,9 ), , ,
.
( 7,8+1,7 /). , , , .
.
36% ( 1), 654,2 , . () . 20% ( 2)
56,22,8 , , .
44% ( 3)
44,34,6 , ,

. 2 3 2
32,30,9 / .
,
, , -

, ,
.


1948
Fuller Allbright, 72- . ,
. Allbright,
Lafferty 3 74 .
Oppenheim et al.
, 61
. 6-8 . Tenover
100
3
[47].

, 5 14%) [29].
-6, f , .
(). 2 : ,
- (, , -250).

(+14% Z-) -250 (+13%> Z-), - (+5% Z) - (+2% Z-).
, , .
6 .

. , ,
.

, . [ , ,
I ,
| . , !
j .

1/2004

1. A min S., Zhang Y., Sawin . ., Evans S.R., . ., Kiel DP.,
Wilson P. W.F., Felson D. T. 2000 Association of hypogonadism and estradiol
levels with bone mineral density in elderly men from the Framingham study.
Ann Intern Med 133:951-963.
2. Bellido ., Jilka R., Boyce ., Girasole G, Broxmeyer H., Dalrymple
S., Murray R., Manolugas S. 1995 Regulation of interleukin-6,
osteoclastogenesis, and bone mass by androgens. J Clin Invest 95:2886-2895.
3.
Bikzikian J. P., Morishimu A., Bell J., Grumbach M. M. 1998 Increased
bone mass as a result of estrogen therapy in a man with aromatase deficiency.
N. Engl. J. Med. 339:599-603.
4. Carani C, Qin K., Simoni M., Fauslini-Fustini M., Serpente S., Boyd
J., Korach K.S., Simpson E.R. 1997 Effect of testosterone and estradiol in a
man with aromatase deficiency. N. Engl. J. Med. 337:91-95.
5.
Center JR., Nguyen T.V., White C.P., Eisman J.A. 1997 Male
osteoporosis predictors: sex hormones and calcitropic hormones. J. Bone Miner
Res. 11:S368.
6. Chen J.R., Kousteni S., Bellido T, Han L, DiGregorio G.B., Jilka
R. L, Manolagas S. 2001 Gender-independent induction of murine osteoclast
apoptosis in vitro by either estrogens or non-aromatizable androgens. J. Bone
Miner Res. 16(Suppl 1):S159.
7. Chow J., Tobias J.H., Colston K. W., Chambers T.J. 1992 Estrogen
maintains trabecular bone volume in rats not only by suppression of bone
resorption but also by stimulation of bone formation. J. Clin. Invest. 89:74
78.
8.
Eriksen E.F., Cohard D.S., Berg N.J. et al. Evidence of estrogen
receptors in normal human osteoblast-like cells. Science. 1988; 241:84-86.
9.
Eriksen E.F., Landgahl., Vesterby A., Rungby J., Kassem M. 1999
Hormone replacement therapy prevents osteoclastic hyperactivity: a
histomorphometric study in early postmenopausal women. J. Bone Miner Res.
14:1217-1221.
10. Falahati-Nini A., Riggs B.L, Atkinson E.J., OTallon W.M., Eastell
R., Khosla S. 2000 Relative contributions of testosterone and estrogen in
regulating bone resorption and formation in normal elderly men. J. Clin. Invest.
106:1553-1560.
11. FeldmanH.A., GolsteinI., HatzichristouD.G., KraneR.J., McKinlay
J.B. Importence and its medical and psychological correlates: results of the
Massachusetts Male Aging Study//J. Urolog. 1994. V. 151. P. 54-61.
12. Gohel A., McCarthy M.B., Gronowicz G. 1999 Estrogen prevents
glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro.
Endocrinology. 140:5339-5347.
13. Greendale G.A., Edelstein S., Barrett-Connor E. 1997 Endogenous
sex steroids and bone mineral density in older women and men: the Rancho
Bernardo study. J Bone Miner Res 12:1833-1843.
14. Grumbach M.M. 2000 Estrogen, bone, growth and sex: a sea change
in conventional wisdom. J Pediatr Endocrinol. Metab.13:1439-1455.
15. Harmon S.M., Mettr E.J., Tobin J.D. et al. Longitudinal effects of
aging on serum total and tree testosteron levels in healthy men. J. Clin. Endocr.
Metab 2001; 86: 724-31.
16. Hughes D.E., Dai A., Tiffee 1, Li H.H., Mundy G.R., Boyce B.F.
1996 Estrogen promotes apoptosis of munne osteoclasts mediated by T G F . Nat Med 2:1132-1136.
17. Jackson J. A., Riggs M. W, SpiekermanA.M. Testosterone deficiency
as a risk factor for hip fractures in men: a case-control study. Am J Med Sci.
1992 Jul;304[l]:4-8.
18. Kaiser F. E., Morlev J. E. Gonadotropins. testosterone and aging male.
Neurobiol. Aging. 1994. V.15. P.559-563.
19. Kasperk ., WergedalJ.E., Farley JR., Linkharl T.A., Turner R. .,
Bavlink D.J. 1989 Androgens directly stimulate proliferation of bone cells in
vitro. Endocrinology 124:1576-1578.
20. KhoslaS., Meltonlll. L.J.. AtkinsonE.J., OFallon W.M., KleeG.G,
Riggs B.L. 1998 Relationship of serum sex steroid levels and bone turnover
markers with bone mineral density in men and women: a key role for
bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274.
21. Komm B.S., Terpening ., Benz D.J. et al. Estrogen binding,
receptor mRNA and biologic response in osteoblast-like osteosarcoma cells.
Science. 1988:241:81-84.
22. Lips P. Vitamin D deficiency and secondary hyperparathyroidism
in the eldery: Consequence for bone los and fracture and therapeutic
implications'Endocr Rev 2001; 22: 477-501.
23. Lunenfeld B. Aging male: editorial article // The aging Male. 1998.
V.I. P. 1-7.
24. Majeska R.J.. Ryaby J. ., Einhorn . 1994 Direct modulation of
osteoblastic activity with estrogen. J Bone Joint Surg Am 76A: 713-721.
25. Manolagas S.C. 2000 Birth and death of bone cells: basic regulatory
mechanisms and implications for the pathogenesis and treatment of
osteoporosis. Endocr Rev 21:115-137.
26. Mason R.A., Morris H.A. 1997 Effects of dihydrotestosterone on
bone biochemical markers in sham and oophorectomized rats. J Bone Miner
Res 12:1431-1437.
27. Melton L.J. III. Epidemiology of fractures. In: Riggs B.L., Melton
L.J. Ill, eds. Osteoporosis, Etiology, Diagnosis, ans Managementt. New York:
Raven Press, 1988: 133-154.
28. Morishima A., Grumbach M.M., Simpson E.R., Fisher C, Qin K. 1995
Aromatase deficiency in male and female siblings caused by a novel mutation
and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698.
29. MorleyJ.E., Perry H.M., Kaiser F.E., KraenzleD., Jensen J., Houston
K., MattammalM., Perry Jr. H.M. Effect of testosterone replacement therapy

in old hypogonadal males: a preliminary study. Journal of the American


Geriatrics Society 1993: 41:149-152.
30. O'Neill T.W., Felsenberg D., Verlaw J. et al. The prevalence of
vertebral deformity in European men and women: The European Vertebral
Osteoporosis Study. J. Bone Miner Res 1996; 11:1010-8.
31. Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S.. Piaseau
N.. Chailurkit L. 1998 Serum oestradiol and oestrogen-receptor gene
polymorphism are associated with bone mineral density independently of serum
testosterone in normal males. Clin Endocrinol (Oxf) 49:803-809.
32. Ongphiphadhanakul B. el al. Serum testosterone and its relation to
bone mineral density and body composition in normal males. Clin Endocrinol
[Oxf], 1995.436]: P. 727-33.
33. Oursler M.J., Osdoby P., Pyfferoen J. et al. Avian osteoclasts as
estrogen target cells. Proc Nat! Acad Sci USA 1991:88:6613-6617.
34. Oursler M.J., Pederson L, Fitzpatrick L. et al. Human giant cell
tumors of the bone (osteoclastomas) are estrogen target cells. J Bone Miner
Res 1992;7:S111.
35. Oz O.K., Zerwekh J.E., Fisher C, Graves K. Nanu L, Millsaps R.,
Simpson E.R. 2000 Bone has a sexually dimorphic response to aromatase
deficiency. J Bone Miner Res 15:507-514.
36. Parfitt A.M. 2000 Skeletal heterogeneity and the purposes of bone
remodeling: implications for the understanding of osteoporosis. In: Marcus
R. Feldman D, Kelsey J, eds. Osteoporosis. 2nd ed. San Diego: Academic
Press; 433-447.
37. Parfitt A.M., Mathews C.H.E., Villaneuva A.R., Kleerekoper M.,
Frame ., Rao D.S. 1983 Relationships between surface, volume, and thickness
of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 72:13961409.
38. Pederson L., Kremer M., Judd J., Pascoe D., Spelsberg T.C., Riggs
B.L, Oursler M.J. 1999 Androgens regulate bone resorption activity of isolated
osteoclasts in vitro. Proc Natl Acad Sci USA 96:505-510.
39. Qu Q., Perala-Heape M., Kapanen A.. DahllundJ., Salo J., Vaananen
H.K., Harkonen P. 1998 Estrogen enhances differentiation of osteoblasts in
mouse bone marrow culture. Bone 22:201-209.
40. Rajaram S., Buylink D.J., Mohan S. 1997 Insulin-like growth factorbinding proteins in serum and other biological fluids: regulation and functions.
Endocr Rev 18:801-831.
41. Schmidt A.. Seedor J. G., Gentile M.A., Pennypacker B.L, Rodan G.A.,
KimmelD.B. 1999 Femoral bone density and length in male and female estrogen
receptor- (ER6) knockout mice. J Bone Miner Res 14(Suppl 1):S456.
42. Slemenda W., Longcope C. Zhou L, Hui S.L.. Peacock M.,
Johnston 1997 Sex steroids and bone mass in older men: positive associations
with serum estrogens and negative associations with androgens. J Clin Invest
100:1755-1759.
43.
SmithE.P., BovdJ., FrankG.R., TakahashiH., CohenR.M., Specker
., Williams T.C., Lubahn D.B., Korach K.S. 1994 Estrogen resistance caused
by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med.
331:1056-1061. "
44. SwerdloffR., Wang Androgens and the aging male. In Textbook
of Men's Health [ed. B.Lunenfeld. L.Gooren] 2002.
45. Szulc P., Munoz F., Claustrat ., Garnero P., Marchand F. 2001
Bioavailable estradiol may be an important determinant of osteoporosis in
men: the MINOS study. J Clin Endocrinol Metab 86:192-199.
46. Tenover J.S., Matsumoto A.M., Plymate S.R., Bremner W.J. 1987
The effects of aging in normal men on bioavailable testosterone and luteinizing
hormone secretion: response to clomiphene citrate. J Endocrinol Metab
65:1118-1126.
47. Tenover J.S. Effects of testosterone supplementation in the aging
male. Journal of Clinical Endocrinology and Metabolism 1992; 75:1092-1098.
48. Turner R. T, Cohard D.S., Spelsberg T.C. 1990 Estrogen inhibition
of periosteal bone formation in rat long bones: down-regulation of gene
expression for bone matrix proteins. Endocrinology. 127:1346-1351.
49. Van den Beld A. W., de Jong F.H.. Grobbee D.E.. Pols H.A.P.,
Lamberts S. W.J. 200 Measures of bioavailable serum testosterone and estradiol
and their relationships with muscle strength, bone density, and body
composition in elderly men. J Clin Endocrinol Metab 85:3276-3282.
50. Vanderschueren D., Van Herck E., Nijs J., Ederveen A.G.H., De Coster
R., Bouillon R. 1997 Aromatase inhibition impairs skeletal modeling and
decreases bone mineral density in growing male rats. Endocrinology 138:2301 2307.
51. VeldhuisJ.D., Melzger D.L., Martha Jr. P.M., Mamas N.. Kerrigan
JR., KeenanB., Rogol A.D., PincusS.M. 1997 Estrogen and testosterone, but
not a nonaromatizable androgen, direct network integration of hypothalamosomatotropc (growth hormone)-insulin-like growth factor I axis in the human:
evidence from pubertal pathophysiology and sex-steroid hormone replacement.
J. Clin. Endocrinol. Metab. 82:3414-3420.
52.
Vermeulen A., Kaufman J.M., Giagulli V.A. Influence of some
biological indexes on sex hormone-binding globulin and androgen levels in
aging or obese males. J. Clin Endocrinol Metab. 1996 May;81[5]:1821-6.
53. Von Schoultz ., Carlstrom K. 1989 On the regulation of sexhormone-binding globulin-a challenge of an old dogma and outlines of an
alternative mechanism. J Steroid Biochem 32:327-334.
54. Wakley G.K.. Schutte Jr. H.D., Hannon K.S., Turner R.T. 1991
Androgen treatment prevents loss of cancellous bone in the orchidectomized
rat. J. Bone Miner Res. 6:325-330.
55. Windahl S.H., Vidal O., Andersson G, Gustafsson J.A., Ohlsson C.
1999 Increased cortical bone mineral content but unchanged trabecular bone
mineral density in female ERM-/- mice. J. Clin. Invest. 104:895-901.

1/2004




26 2004


, 1 - ( - ..
). . : , , ,
, . .. ,
23, 2, -.

.
,
(DXA),
.
, .


. , 75%
. ().
,
DXA-: , ,
( ) . .
- ,

-. .
, -

, . - .

, , . , ,

.

:
1. - DXA-. DXA-
( )
.
2. - DXA-
.
3.
, , ,
, .
4. .

, , .
5.
.
6. .
..